The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma - A Review

摘要

The drug category of Sodium-Glucose co-transporters 2 inhibitors (SGLT 2 inhibitors) is a newer class ofpharmaceutical agents for the management of type-2 diabetes mellitus, with a proved promising cardio-protectiveeffects. In addition to above beneficial effects, Sodium-Glucose co-transporters 2 inhibitors showed their effectivenessto reduce abdominal fat content, amount of fat in liver tissues and progression of inflammation and fibrosis inexperimental as well as clinical studies. Non-Alcoholic Fatty Liver Diseases (NAFLD) are common among patientswith type 2 diabetes patients and includes fatty liver, Non-Alcoholic Steato-Hepatitis (NASH) and cirrhosis andwhen present together these disorders exacerbates each other deleterious consequences. This review article is carriedout with an objective to find out the effects of Sodium-Glucose co-transporters 2 inhibitors on non-alcoholic fattyliver diseases, steato-hepatitis, fibrosis liver and hepatocellular carcinoma. The authors identified 21 relevant articlesincluding twelve experimental and nine clinical studies with inclusion of 15152 patients, in study period ranges from20-104 weeks. The analysis of these studies showed beneficial effects SGLT 2 inhibitors on fatty liver, liver functionand NASH development, hepatic fibrosis and prevention and regression of hepatocellular carcinoma and concludedthat SGLT-2 inhibitors may protect or reduce the incidence of non-alcoholic fatty liver diseases, steato-hepatitis andhepatic fibrosis in type 2 diabetes patients.